SUNY, NYU, Galderma Sue Generics Firm Mylan for Allegedly Infringing Rosacea Rx IP

Although SUNY and NYU's financial stake in the proceedings is unclear, they are seeking to protect a royalty stream that dates back to a 1992 licensing agreement with Galderma predecessor Collagenix Pharmaceuticals for some of the patents protecting Oracea, which exceeded $50 million in sales in 2007.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.